Table 1 Summary of patient characteristics for the NEO study and I-SPY validation set
Characteristics | NEO cohort (50) | NEO cohort PT-TM pairs (23) | p value | I-SPY 1 PT-T2 pairs (36) | p value |
|---|---|---|---|---|---|
Median age at diagnosis | 50.8 | 50.1 | 0.8 | 47 | |
Tumour grade | 0.52 | 0.58 | |||
1 | 0 (0%) | 0 (0%) | 1 (3%) | ||
2 | 22 (44%) | 12 (52%) | 20 (55%) | ||
3 | 28 (56%) | 11 (48%) | 15 (42%) | ||
Hormone receptor status | 0.24 | 0.66 | |||
Positive | 23 (46%) | 14 (61%) | 24 (67%) | ||
Negative | 27 (54%) | 9 (39%) | 12 (33%) | ||
HER2 status | 0.87 | 0.64 | |||
Positive | 10 (20%) | 5 (22%) | 6 (17%) | ||
Negative | 40 (80%) | 18 (78%) | 30 (83%) |